Shanghai De Novo Pharmatech announcedachievement of important First-in-Human milestone in China in phase I Trialswith the novel investigational ATR inhibitor DN020198. This Phase I study is designedto investigate the safety, tolerability, pharmacokinetics/pharmacodynamics andpreliminary antitumor activity of DN020198 in Chinese patients with advancedsolid tumors (CTR20231411).